Advanced Oncotherapy (AVO) – Director dealing
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, Non-Executive Director of the Company, purchased 100,000 ordinary shares of 25 pence in the Company at a price of 17.75 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 1,223,946 Ordinary Shares, representing 1.51% of the […]
Advanced Oncotherapy (AVO) – Non-exec Professor Steve Myers buys 400,000 shares at 26p.
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Professor Steve Myers, Non-Executive Director of the Company, has purchased today a total of 400,000 ordinary shares of 25 pence in the Company at a price of 26 pence per Ordinary Share. Following this transaction, Professor Myers holds 450,569 Ordinary […]
Advanced Oncotherapy (AVO) – Non-Exec Professor Chris Nutting buys 202,500 shares at 24.67p
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that on Monday 8th and Tuesday 9th May 2017, Professor Chris Nutting, Non-Executive Director of the Company, purchased a total of 202,500 ordinary shares of 25 pence in the Company at an average price of 24.67 pence per Ordinary Share. […]
Advanced Oncotherapy (AVO) – Non-Exec Dr Nick Plowman invests GBP250,000 at 30p per share
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Nick Plowman, Non-Executive Director, will invest £250,000 in the Company. The investment will be satisfied through the issue of 833,333 new ordinary shares of 25 pence nominal value in the capital of the Company at a price of […]
Advanced Oncotherapy (AVO) – Executive Chairman buys 200,000 shares
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that, yesterday, Dr Mike Sinclair purchased 200,000 Ordinary Shares of 25 pence in the Company at an average price of 30.44 pence per Ordinary Share. Following this transaction, Dr Sinclair now holds 4,928,229 Ordinary Shares, representing 6.65% of the issued […]
Advanced Oncotherapy (AVO) – Director Dealing
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday, Dr Enrico Vanni purchased 100,000 Ordinary Shares of 25 pence in the Company at a price of 26.96 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 1,123,946 Ordinary Shares, representing 1.52% of the issued share […]